Release the brake on muscle
AAV / Plasmid Gene Therapies.
One treatment. Months - Years of sustained muscle gains, strength and metabolic resilience — through the same molecular pathway your body already uses to grow tissue.
Format
Single AAV Infusion
Expression
Sustained 12+ Months
After thirty, you lose roughly 1% of skeletal muscle per year. Myostatin is the governor — and as you age, it tightens.
Follistatin is the body's natural counter to myostatin. It binds and inactivates it in circulation — releasing the brake on muscle growth and metabolic activity.
This therapy uses a single AAV gene therapy infusion to give your muscle cells the genetic instructions to produce more follistatin on their own. Quietly. Continuously. For months at a time.
Unlike a peptide or hormone, you don't keep dosing. After one treatment, follistatin expression rises within weeks and remains elevated through the year.
What follistatin gene therapy does.
01
Myostatin Inhibition
Elevated follistatin neutralizes myostatin before it can dock on muscle-cell receptors.
02
Sustained Expression
A single AAV infusion drives follistatin output for 12+ months — no continuous dosing.
03
Body Composition Shift
Lean mass up, body fat down, grip strength and VO₂ max trend upward through quarterly tracking.
04
Metabolic Resilience
More muscle = more insulin-sensitive tissue. Downstream gains in cardiometabolic markers.
The protocol.
Step I
Consultation
A 45-minute private consultation with Dr. Goel — goals, history, biomarkers, every question answered.
Step II
Candidacy Workup
Hormones, inflammatory markers, DEXA, cardiometabolic panel, baseline follistatin/myostatin. 2–3 weeks.
Step III
Treatment
Single intramuscular AAV follistatin gene therapy infusion at the partner clinic best matched to your protocol. Same-day discharge.
Step IV
Quarterly Tracking
Lean mass, strength, VO₂ max, metabolic markers, biological age — every three months for 12 months.
+3.4 kg
Lean muscle mass
Dr. Goel n=1, M0→M6
−2.1%
Body fat
Self-experiment, quarterly tracker
+42%
Serum follistatin
Sustained expression at month 6
−1.8 yrs
Biological age
Epigenetic clock, M0→M6
I'm running this protocol on myself.
I started follistatin gene therapy as a one-year experiment. Every quarter, I publish the biomarkers — muscle, fat, strength, follistatin expression, biological age. The data below is mine.Dr. Sanjeev Goel · Peak Human
Placeholder data · live tracker updated quarterly · n=1 self-experiment
Your body already has the brake.
And the release.
Muscle growth is a constant tug-of-war between two proteins. As you age, the balance tips against you. This therapy tips it back.
Myostatin is muscle's governor.
After thirty, you lose roughly 1% of skeletal muscle per year. That's not vanity — muscle is the largest insulin-sensitive tissue you own.
A major driver of that loss is myostatin. Its job is to put a ceiling on how much muscle you can build. With age, you produce more of it.
People born with naturally low myostatin develop extraordinary muscle from birth — with no documented ill effects.
The molecular interception, frame by frame.
Myostatin (red) attempts to bind muscle-cell receptors. Follistatin (gold), now produced in elevated amounts by your own cells, intercepts and neutralizes it before it can dock. The receptor stays clear. Growth signals resume.
Who this is for.
Ideal Candidate
- +You're 40+ with measurable strength, muscle, or recovery decline
- +Athlete or high-performer seeking sustained anabolic support without continuous dosing
- +Comfortable with an investigational therapy and structured quarterly tracking
- +Prepared to commit to a full 12-month protocol
Not the Right Fit
- −Active cancer, recent malignancy, or hereditary cancer syndrome
- −Pregnant, breastfeeding, or planning pregnancy within 12 months
- −Active autoimmune disease (case-by-case review)
- −Actively competing athlete subject to WADA testing
Follistatin gene therapy from $25,000.
Final cost depends on the type of follistatin gene therapy and the strength of the dose — matched to your goals and physiology during your $300 consultation with Dr. Goel.
Follistatin gene therapy is currently investigational and is not approved by the FDA or Health Canada for cosmetic, athletic, or longevity indications. Treatment is administered at qualified partner facilities under medical supervision. Outcomes are individual and based on early-stage human data; long-term effects continue to be characterized. This is exactly why Dr. Goel is running the protocol on himself first — and publishing the results.
Book a Consultation Now.
Tell us where you are and we'll match you to the right pathway. A specialist will reply within one business day.
Or take the self-guided assessment